AU2002253999A1 - Ascorbic acid analogs for metalloradiopharmaceuticals - Google Patents
Ascorbic acid analogs for metalloradiopharmaceuticalsInfo
- Publication number
- AU2002253999A1 AU2002253999A1 AU2002253999A AU2002253999A AU2002253999A1 AU 2002253999 A1 AU2002253999 A1 AU 2002253999A1 AU 2002253999 A AU2002253999 A AU 2002253999A AU 2002253999 A AU2002253999 A AU 2002253999A AU 2002253999 A1 AU2002253999 A1 AU 2002253999A1
- Authority
- AU
- Australia
- Prior art keywords
- metalloradiopharmaceuticals
- ascorbic acid
- acid analogs
- analogs
- ascorbic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/121—Solutions, i.e. homogeneous liquid formulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27138901P | 2001-02-26 | 2001-02-26 | |
| US60/271,389 | 2001-02-26 | ||
| PCT/US2002/005155 WO2002067859A2 (en) | 2001-02-26 | 2002-02-22 | Ascorbic acid analogs for metalloradiopharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002253999A1 true AU2002253999A1 (en) | 2002-09-12 |
Family
ID=23035343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002253999A Abandoned AU2002253999A1 (en) | 2001-02-26 | 2002-02-22 | Ascorbic acid analogs for metalloradiopharmaceuticals |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6713042B2 (https=) |
| EP (1) | EP1365813A4 (https=) |
| JP (1) | JP2004529884A (https=) |
| CN (1) | CN1503680A (https=) |
| AU (1) | AU2002253999A1 (https=) |
| BR (1) | BR0207315A (https=) |
| CA (1) | CA2438204A1 (https=) |
| CZ (1) | CZ20032597A3 (https=) |
| HU (1) | HUP0304083A2 (https=) |
| IL (1) | IL157359A0 (https=) |
| MX (1) | MXPA03007595A (https=) |
| WO (1) | WO2002067859A2 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10305463A1 (de) * | 2003-02-04 | 2004-08-12 | Schering Ag | Enantiomerenreines (4S,8S)- und (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triza-3N,6N,9N-tricarboxymethyl-1,11-undecandisäure und deren Abkömmlinge, Verfahren zu deren Herstellung und Verwendung zur Herstellung pharmazeutischer Mittel |
| US20050089471A1 (en) * | 2003-10-24 | 2005-04-28 | Johnson Bruce F. | Labeled ligands for lectin-like oxidized low-density lipoprotein receptor (LOX-1) |
| US20050089470A1 (en) * | 2003-10-24 | 2005-04-28 | Johnson Bruce F. | Labeled peptides for lectin-like oxidized low-density lipoprotein receptor (LOX-1) |
| US20060210479A1 (en) * | 2004-08-10 | 2006-09-21 | Dow Global Technologies Inc. | Targeting chelants and chelates |
| GB0427392D0 (en) * | 2004-12-15 | 2005-01-19 | Amersham Plc | Stabilised 99mTc compositions |
| TW200803903A (en) * | 2006-04-28 | 2008-01-16 | Nihon Mediphysics Co Ltd | Novel compound having affinity to amyloid |
| RU2008150377A (ru) * | 2006-05-19 | 2010-06-27 | Нихон Меди-Физикс Ко., Лтд. (Jp) | Новое соединение, обладающее сродством к амилоиду |
| CN101501033B (zh) * | 2006-06-21 | 2012-08-01 | 通用电气医疗有限公司 | 对淀粉状蛋白具有亲和性的化合物 |
| PL2029178T3 (pl) * | 2006-06-21 | 2012-08-31 | Ge Healthcare Ltd | Produkty radiofarmaceutyczne |
| WO2008056481A1 (en) * | 2006-11-09 | 2008-05-15 | Nihon Medi-Physics Co., Ltd. | Radioactive diagnostic imaging agent |
| KR20090091287A (ko) * | 2006-11-17 | 2009-08-27 | 니혼 메디피직스 가부시키가이샤 | 신규 아밀로이드 친화성 화합물 |
| EP2098522B1 (en) * | 2006-11-30 | 2011-10-19 | Nihon Medi-Physics Co., Ltd. | Compounds having affinity for amyloid |
| PL2106808T3 (pl) * | 2006-12-21 | 2018-07-31 | Nihon Medi-Physics Co., Ltd. | Promieniotwórczy znacznik do obrazowania diagnostycznego zawierający kwas 1-amino-3-[18F]fluorocyklobutanokarboksylowy |
| TWI406674B (zh) | 2007-02-13 | 2013-09-01 | 日本藥學物理公司 | Method for manufacturing diagnostic radiographic diagnostic agents |
| GB0718386D0 (en) * | 2007-09-21 | 2007-10-31 | Ge Healthcare As | Improved radiopharmaceutical formulation |
| TW200918102A (en) * | 2007-10-24 | 2009-05-01 | Nihon Mediphysics Co Ltd | Novel compound having affinity for amyloid |
| CN101909658A (zh) * | 2007-10-30 | 2010-12-08 | 日本医事物理股份有限公司 | 对淀粉样蛋白具有亲和性的新化合物的应用及制备方法 |
| KR20100089858A (ko) * | 2007-10-30 | 2010-08-12 | 니혼 메디피직스 가부시키가이샤 | 신규 아밀로이드 친화성 화합물의 사용 및 제조 방법 |
| WO2009073698A1 (en) * | 2007-12-04 | 2009-06-11 | Bracco Imaging S.P.A. | Homogenization of a radiopharmaceutical using sonification and/or rotor-stator technology to produce a homogenous suspension, emulsion, mixture or solid suspension of immiscible ingredients |
| RU2011112946A (ru) * | 2008-09-05 | 2012-10-10 | Молекьюлар Инсайт Фармасьютикалз, Инк. (Us) | Фармацевтическая композиция радиойодированного бензамидного производного и способы ее получения |
| FR2942227B1 (fr) * | 2009-02-13 | 2011-04-15 | Guerbet Sa | Utilisation de tampons pour la complexation de radionucleides |
| KR101602992B1 (ko) | 2009-04-15 | 2016-03-11 | 랜티우스 메디컬 이메징, 인크. | 아스코르브산을 사용한 방사성 약제 조성물의 안정화 |
| US9321095B2 (en) | 2010-06-30 | 2016-04-26 | General Electric Company | Apparatuses and methods for cutting porous substrates |
| WO2013093099A1 (en) * | 2011-12-22 | 2013-06-27 | Piramal Imaging Sa | Stabilization of peptidic radiopharmaceuticals using uric acid or derivatives thereof |
| CN104470547B (zh) | 2012-05-24 | 2018-01-26 | 未来化学株式会社 | 利用筒状物合成放射性药物的方法 |
| US20140147381A1 (en) * | 2012-11-29 | 2014-05-29 | Gregory David Espenan | 89zr compounds, to include somatostatin, apparatus and products comprising such compounds, methods of making same, and methods of using same for radio imaging and/or treatment |
| JP2016510342A (ja) * | 2013-02-15 | 2016-04-07 | トーマス・ジェファーソン・ユニバーシティThomas Jefferson University | 腫瘍画像化のためのキット |
| KR101652204B1 (ko) * | 2014-11-27 | 2016-08-29 | (주)셀트리온 | 펩타이드가 결합된 안정한 아스코르빈산 유도체, 그의 제조방법 및 그를 포함하는 화장료 조성물 |
| TWI604853B (zh) * | 2016-05-03 | 2017-11-11 | 行政院原子能委員會核能研究所 | 放射免疫複合體、診療劑及套組 |
| CN107167540B (zh) * | 2017-07-08 | 2019-07-30 | 万舒(北京)医药科技有限公司 | 测定人尿液生物样品中的DTPA-Zn的方法 |
| KR102207372B1 (ko) * | 2020-03-31 | 2021-01-27 | 재단법인 아산사회복지재단 | 방사성 의약품의 안정화제 및 이를 포함하는 방사성 의약 조성물 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL42204A (en) * | 1972-05-08 | 1976-09-30 | Solco Basel Ag | Process and apparatus for the manufacture of injectable radionuclide preparations |
| US4504462A (en) * | 1982-06-10 | 1985-03-12 | Mallinckrodt, Inc. | Process for making a lyophilized product for use in skeletal imaging |
| US4707353A (en) * | 1982-12-08 | 1987-11-17 | Mallinckrodt, Inc. | Radiographic imaging agents |
| US5985240A (en) * | 1989-08-09 | 1999-11-16 | Rhomed Incorporated | Peptide radiopharmaceutical applications |
| DK0422713T3 (da) * | 1989-10-09 | 1995-04-10 | Unilever Plc | Spiseligt smøremateriale |
| DK0600992T3 (da) * | 1991-08-29 | 2000-10-09 | Mallinckrodt Medical Inc | Anvendelse af gentissyre eller gentisylalkohol til stabilisering af radiomærkede peptider og proteiner |
| GB9417873D0 (en) | 1994-09-06 | 1994-10-26 | Sandoz Ltd | Organic compounds |
| WO1997028181A2 (en) * | 1996-02-02 | 1997-08-07 | Rhomed Incorporated | Post-labeling stabilization of radiolabeled proteins and peptides |
| US6066309A (en) * | 1996-02-02 | 2000-05-23 | Rhomed Incorporated | Post-labeling stabilization of radiolabeled proteins and peptides |
| US5961955A (en) * | 1997-06-03 | 1999-10-05 | Coulter Pharmaceutical, Inc. | Radioprotectant for peptides labeled with radioisotope |
| CA2413538A1 (en) * | 2000-07-06 | 2002-01-17 | Bristol-Myers Squibb Pharma Company | Stable radiopharmaceutical compositions and methods for preparation thereof |
-
2002
- 2002-02-22 JP JP2002567231A patent/JP2004529884A/ja active Pending
- 2002-02-22 WO PCT/US2002/005155 patent/WO2002067859A2/en not_active Ceased
- 2002-02-22 HU HU0304083A patent/HUP0304083A2/hu unknown
- 2002-02-22 MX MXPA03007595A patent/MXPA03007595A/es active IP Right Grant
- 2002-02-22 AU AU2002253999A patent/AU2002253999A1/en not_active Abandoned
- 2002-02-22 IL IL15735902A patent/IL157359A0/xx unknown
- 2002-02-22 CN CNA028087186A patent/CN1503680A/zh active Pending
- 2002-02-22 CZ CZ20032597A patent/CZ20032597A3/cs unknown
- 2002-02-22 EP EP02723206A patent/EP1365813A4/en not_active Withdrawn
- 2002-02-22 CA CA002438204A patent/CA2438204A1/en not_active Abandoned
- 2002-02-22 BR BR0207315-3A patent/BR0207315A/pt not_active IP Right Cessation
- 2002-02-22 US US10/081,258 patent/US6713042B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1365813A4 (en) | 2006-03-22 |
| CA2438204A1 (en) | 2002-09-06 |
| JP2004529884A (ja) | 2004-09-30 |
| WO2002067859A2 (en) | 2002-09-06 |
| IL157359A0 (en) | 2004-02-19 |
| US6713042B2 (en) | 2004-03-30 |
| WO2002067859A3 (en) | 2002-11-28 |
| US20020122769A1 (en) | 2002-09-05 |
| CN1503680A (zh) | 2004-06-09 |
| MXPA03007595A (es) | 2003-12-04 |
| HUP0304083A2 (hu) | 2004-03-29 |
| BR0207315A (pt) | 2004-02-10 |
| EP1365813A2 (en) | 2003-12-03 |
| CZ20032597A3 (cs) | 2004-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002253999A1 (en) | Ascorbic acid analogs for metalloradiopharmaceuticals | |
| AU2002349297A1 (en) | Statin-like compounds | |
| AU2002253675A1 (en) | Chromene compound | |
| AU2002360487A1 (en) | Acyclovir-peptide analogs | |
| AU2002357602A1 (en) | Adsorbent for phosphoric acid | |
| AU2002359165A1 (en) | Novel compounds | |
| AU2002349677A1 (en) | Chromene compound | |
| AU2002350942A1 (en) | Imidazolidineacetic acid derivatives | |
| AU2002310684A1 (en) | Vitamin D analogues | |
| AU2001296775A1 (en) | Triptycene analogs | |
| EP1425258A4 (en) | ANALOGUES OF HYDROXYEICOSENOIC ACID | |
| AU6550800A (en) | Hepoxilin analogs | |
| AUPR755501A0 (en) | Cyclic compound | |
| AUPR920301A0 (en) | Neurologically-active compounds | |
| AU2002342940A1 (en) | New pharmaceutical compounds | |
| AU2002366040A1 (en) | Novel tetronic acid derivative | |
| AUPR520201A0 (en) | Antiviral compounds | |
| AU2002244978A1 (en) | Alpha-substituted omega-arylfatty acid derivative | |
| AU2002361987A1 (en) | Substituted beta-aminoalcohols used as medicaments | |
| AU2001285801A1 (en) | 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acid derivates | |
| AU2002314307A1 (en) | Composition containing 2-aminophenylacetic acid | |
| AU2291600A (en) | New vitamin d analogs | |
| AU2004201666B2 (en) | 4-Imidazolin-2-one compounds | |
| AUPR738001A0 (en) | Compound for medicinal purposes | |
| AU2002347439A1 (en) | Isobenzofuran derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |